Antonio Berlanga Ruiz
Antonio chairs the Finance and Operations committees at PSNResearch, and has served since 2010 as a Director on the Board.
Learn More about Antonio
Rafael Zurita, MSc
Rafael is our General Manager, and is responsible for driving the company's growth as an agile and adaptive clinical development firm.
Read More About Rafael
Paul Bishop
Paul leads all business development efforts at PSNResearch.

Learn More About Paul
Michael Gierend, DVM, Ph.D.
A Founding Partner of PSNResearch, Michael has served in many leadership capacities since our inception in 1997.
See Michael's Expertise
Ignazio Di Giovanna, Ph.D.
Ignazio is PSNResearch's Head of Quality Assurance and expert in First-In-Man trials.
See Ignazio's Accomplishments
Alejandra Mørk, Ph.D.
Alejandra leads our Drug Development Consulting team, with additional specialities in Clinical Trial Supply.
Read About Alejandra
Alain Baleydier
Alain is expert in clinical studies, he has more than 25 years of experience in the rheumatologic / immunologic fields.
Learn More About Alain
Frédéric Mistretta
Frédéric is the co-leader of the AFCROs Real World Studies working group.
Read More about Frédéric
Jean-Sylvain Larguier, M.D
Jean-Sylvain is the co-leader of the AFCROs Medical Devices working group.
Read about Jean-Sylvain
Odette Jochems, M.D.
Odette brings 36 years of experience with the Dutch healthcare system and its regulatory bodies.

Read About Odette
Lyle Camblos
Lyle leads PSNResearch's Finance and Operations teams, and brings his experience in business operations to the unique challenges of international project management.
Learn More About Lyle
Pino Fioravanti, M.D.
Pino has huge experience in planning and managing phase 1-4 clinical programs in about all the medical fields.
Read More about Pino

IctalCare launches CE-marked M1 Epilepsy Alarm

IctalCare's success story results from our contribution to their clinical development process: protocol writing, monitoring, data management, statistics, and reporting
Learn more

Arzerra EMA/FDA approved following successful pivotal Phase III trial

Planning, conduct and reporting of a pivotal, phase 3 clinical trial in chronic lymphocytic leukemia (CLL) - 225 patients, 13 countries - resulted in full approval.
Speak With This Partner

Paedriatric Investigational Plan complete and approved for METFIZZ

Our regulatory/medical affairs team has been awarded a EU’s Seventh Framework Programme for Research (FP7) grant for the Phase III study.
Read More